NRx Pharmaceuticals Inc.
NRXP | NASDAQ
$3.25
-$0.04 (-1.22%)
Sep 22, 2026, 11:27 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Net Income | -28.62M | -25.13M | -30.15M | -39.75M | -93.06M | -51.78M |
Depreciation & Amortization | 143K | 5K | 5K | 4K | 2K | 2K |
Stock-Based Compensation | 228K | 486K | 387K | 3.63M | 7.79M | 730K |
Other Working Capital | 1.25M | 10.51M | 2.51M | 2.31M | -5.71M | 3.1M |
Other Non-Cash Items | 12.73M | 8.71M | 2.94M | -4.33M | 52.47M | 45.33M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 1.41M | 5.29M | 5.16M | 699K | -4.9M | 3.45M |
Operating Cash Flow | -14.11M | -10.64M | -21.66M | -39.76M | -37.7M | -2.27M |
Capital Expenditures | n/a | n/a | -3K | -10K | -7K | -2K |
Cash Acquisitions | -2.38M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -432K | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -2.81M | n/a | -3K | -10K | -7K | -2K |
Debt Repayment | 4.68M | -1.5M | -3.09M | 9.5M | -1.28M | 620K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -350K | 3.07M | n/a | 10K | 27.75M | n/a |
Financial Cash Flow | 23.28M | 7.49M | 6.2M | 32.21M | 63.46M | 3.25M |
Net Cash Flow | 6.35M | -3.15M | -15.46M | -7.55M | 25.75M | 982K |
Free Cash Flow | -14.11M | -10.64M | -21.66M | -39.77M | -37.71M | -2.27M |
Adj. Free Cash Flow | -14.34M | -11.12M | -22.05M | -43.39M | -45.5M | -3M |
Maintenance CapEx | n/a | n/a | -3K | -4K | -2K | -2K |
Growth CapEx | n/a | n/a | n/a | -6K | -5K | n/a |
Owner Earnings | -14.11M | -10.64M | -21.66M | -39.76M | -37.71M | -2.27M |
Add to Watchlist
Select watchlists to add or remove NRXP